Back to Search Start Over

In vitro electrophysiological drug testing on neuronal networks derived from human induced pluripotent stem cells.

Authors :
Parodi G
Zanini G
Collo L
Impollonia R
Cervetto C
Frega M
Chiappalone M
Martinoia S
Source :
Stem cell research & therapy [Stem Cell Res Ther] 2024 Nov 17; Vol. 15 (1), pp. 433. Date of Electronic Publication: 2024 Nov 17.
Publication Year :
2024

Abstract

Background: In vitro models for drug testing constitute a valuable and simplified in-vivo-like assay to better comprehend the biological drugs effect. In particular, the combination of neuronal cultures with Micro-Electrode Arrays (MEAs) constitutes a reliable system to investigate the effect of drugs aimed at manipulating the neural activity and causing controlled changes in the electrophysiology. While chemical modulation in rodents' models has been extensively studied in the literature, electrophysiological variations caused by chemical modulation on neuronal networks derived from human induced pluripotent stem cells (hiPSCs) still lack a thorough characterization.<br />Methods: In this work, we created three different configurations of hiPSCs-derived neuronal networks composed of fully glutamatergic neurons (100E), 75% of glutamatergic and 25% of GABAergic neurons (75E25I) and fully GABAergic neurons (100I). We focused on the effects caused by antagonists of three of the most relevant ionotropic receptors of the human brain, i.e., 2-amino-5-phosphonovaleric (APV, NMDA receptors antagonist), 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, AMPA receptors antagonist), and bicuculline, picrotoxin and pentylenetetrazole (BIC, PTX, and PTZ, respectively, GABA <subscript>A</subscript> receptors antagonists).<br />Results: We found that APV and CNQX completely abolished the network bursting activity and caused major changes in the functional connectivity. On the other hand, the effect of BIC, PTX and PTZ mostly affected configurations in which the inhibitory component was present by increasing the firing and network bursting activity as well as the functional connectivity.<br />Conclusions: Our work revealed that hiPSCs-derived neuronal networks are very sensitive to pharmacological manipulation of the excitatory ionotropic glutamatergic and inhibitory ionotropic GABAergic transmission, representing a preliminary and necessary step forward in the field of drug testing that can rely on pathological networks of human origin.<br />Competing Interests: Declarations Ethics approval and consent to participate The experimental protocol was approved by the European Animal Care Legislation (2010/63/EU), by the Italian Ministry of Health in accordance with the D.L. 116/1992 and by the guidelines of the University of Genova (Prot. 75F11.N.6JI, 08/08/2018). We received the Ngn2-positive and Ascl1-positive hiPSCs lines in frozen vials, kindly provided by Prof. Nadif Kasri (Radboud University Medical Centre, the Netherlands). The genetically modified organism (GMO) approval under which the lines have been used is IG22-071. The two lines provided by our collaborators were previously characterized [21]. The lines were infected, according to a previously published protocol [10], with lentiviral constructs encoding rtTA combined with Ngn2 (Control line 1) or Ascl1 (Control line 2) to generate doxycycline-inducible excitatory or inhibitory neurons arrays [21, 22]. Both lines were generated from reprogrammed fibroblasts. Control line 1 (C1, healthy 30-years-old female, Ngn2) was reprogrammed via episomal reprogramming (Coriell Institute for medical research, GM25256). Control line 2 (C2, healthy 51-years-old male, Ascl1) was reprogrammed via a non-integrating Sendai virus (KULSTEM iPSC core facility Leuven, Belgium, KSF-16-025). Karyotypes of hiPSCs lines were verified, and hiPSCs lines were tested for pluripotency and genomic integrity based on single nucleotide polymorphism arrays [21, 22]. We declare that the research was conducted in accordance with the principles embodied in the Declaration of Helsinki and in accordance with local statutory requirements. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
1757-6512
Volume :
15
Issue :
1
Database :
MEDLINE
Journal :
Stem cell research & therapy
Publication Type :
Academic Journal
Accession number :
39551784
Full Text :
https://doi.org/10.1186/s13287-024-04018-2